Overview

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

Status:
Not yet recruiting
Trial end date:
2027-08-15
Target enrollment:
Participant gender:
Summary
This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD.
Phase:
Phase 2
Details
Lead Sponsor:
Cognition Therapeutics